| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Tamoxifen N-oxide targets the same estrogen receptor (ER) pathway as tamoxifen, but with different activity. Tamoxifen N-oxide has known anti-estrogen activity. The compound is a metabolite that contributes to the overall pharmacological effect of tamoxifen treatment, although its individual receptor binding affinity has not been fully characterized. It is also a substrate for cytochrome P450 enzymes.
|
|---|---|
| ln Vitro |
In vitro, the effects mediated by tamoxifen N-oxide are still poorly understood. Tamoxifen N-oxide has been studied in MCF-7 breast cancer cells for its growth inhibition effects, but its potency is lower compared to the active metabolites 4-hydroxytamoxifen and endoxifen. Tamoxifen N-oxygenation represents a detoxication pathway, with the caveat that N-oxides can be reduced back to the parent amines.
|
| ln Vivo |
In vivo, the concentrations of tamoxifen and its metabolites in tumor tissues are significantly correlated to their serum levels, with the exception of tamoxifen N-oxide. This suggests tissue distribution patterns differ from other metabolites. The anticancer effect of tamoxifen is believed to be due to its metabolites 4-hydroxytamoxifen and endoxifen, while tamoxifen N-oxide likely plays a less significant role but may undergo reduction to regenerate active species.
|
| Enzyme Assay |
Tamoxifen N-oxide can be used in non-cellular enzyme assays as a substrate for cytochrome P450 enzymes or as a standard for analytical method development. For in vitro assays, the compound is dissolved in an appropriate organic solvent (e.g., DMSO or methanol) to prepare a stock solution. It is then added to enzyme reaction mixtures containing microsomes or purified enzymes to study N-oxide reduction or further oxidative metabolism. Samples are analyzed by LC-MS to monitor substrate depletion and product formation.
|
| Cell Assay |
Tamoxifen N-oxide is used as an analytical standard for the quantification of this metabolite in cell-based studies. For example, MCF-7 breast cancer cells are treated with tamoxifen, and culture media are collected. Tamoxifen N-oxide is added to the samples as an internal standard at a fixed concentration. Following solid-phase extraction or protein precipitation, the samples are analyzed by LC-MS/MS to quantify tamoxifen and its metabolite levels, providing insights into cellular metabolism and drug disposition.
|
| Animal Protocol |
Tamoxifen N-oxide can be used as a reference standard in animal studies. In rodent xenograft models, tamoxifen is administered orally or intraperitoneally, and plasma and tumor tissues are collected. The metabolite standard is spiked into samples at a known concentration before extraction and LC-MS analysis to quantify tamoxifen N-oxide levels. This provides data on the in vivo metabolism, tissue distribution, and exposure of tamoxifen and its metabolites in preclinical models.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Tamoxifen N-oxide's known metabolites include α-hydroxytamoxifen N-oxide. Tamoxifen N-oxide is a metabolite and its PK properties are derived from tamoxifen administration. After oral tamoxifen (20 mg), N-oxygenation produces tamoxifen N-oxide with individual metabolite levels varying based on CYP enzyme activity. Tumor tissue levels of tamoxifen and its metabolites are 5-10 times higher than those measured in serum, with the exception of tamNox, suggesting different tissue distribution. The plasma half-life of tamoxifen is approximately 5-7 days. |
| Toxicity/Toxicokinetics |
Tamoxifen N-oxide as a metabolite has similar safety considerations as its parent drug. Tamoxifen is generally well-tolerated, but side effects include hot flashes, nausea, and increased risk of endometrial cancer and thromboembolic events. The N-oxygenation pathway is generally considered a detoxication pathway. As a reference standard, standard laboratory precautions for handling antiestrogenic compounds (gloves, safety glasses) are recommended. Not intended for human consumption.
|
| References |
[1]. Foster AB, et al. Metabolism of tamoxifen by rat liver microsomes: formation of the N-oxide, a new metabolite. Biochem Pharmacol. 1980 Jul 1;29(13):1977-9.
|
| Additional Infomation |
Tamoxifen N-oxide is a tertiary amine oxide, formed by the oxidation of the amino group of tamoxifen. It is both a metabolite and an anti-estrogen. It is an aromatic ether and also a tertiary amine oxide. Functionally, it is related to tamoxifen. It is derived from the hydride of stilbenes.
Tamoxifen N-oxide is not a drug but a phase I oxidative metabolite of tamoxifen. It has no approved therapeutic status as a standalone agent. It is used as an analytical reference standard in pharmaceutical research, clinical diagnostics, and forensic toxicology for tamoxifen metabolite profiling. It is also used in studies of drug metabolism, CYP450 enzyme activity, and as a standard for LC-MS/MS quantification in biological samples for therapeutic drug monitoring and pharmacokinetic studies. |
| Molecular Formula |
C26H29NO2
|
|---|---|
| Molecular Weight |
387.51
|
| Exact Mass |
387.22
|
| CAS # |
75504-34-6
|
| PubChem CID |
3033895
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.029
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
507
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC/C(=C(\c1ccccc1)/c2ccc(cc2)OCC[N+](C)(C)[O-])/c3ccccc3
|
| InChi Key |
YAASNACECBQAFW-QPLCGJKRSA-N
|
| InChi Code |
InChI=1S/C26H29NO2/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)29-20-19-27(2,3)28/h5-18H,4,19-20H2,1-3H3/b26-25-
|
| Chemical Name |
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine oxide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5806 mL | 12.9029 mL | 25.8058 mL | |
| 5 mM | 0.5161 mL | 2.5806 mL | 5.1612 mL | |
| 10 mM | 0.2581 mL | 1.2903 mL | 2.5806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
